Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Sales and DivestituresNet Cash FlowNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biote (BTMD) Asset Writedowns and Impairment (2021 - 2025)

Historic Asset Writedowns and Impairment for Biote (BTMD) over the last 5 years, with Q3 2025 value amounting to $486000.0.

  • Biote's Asset Writedowns and Impairment rose 56575.34% to $486000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year increase of 12789.47%. This contributed to the annual value of $1.5 million for FY2024, which is 12473.6% up from last year.
  • Per Biote's latest filing, its Asset Writedowns and Impairment stood at $486000.0 for Q3 2025, which was up 56575.34% from $327000.0 recorded in Q2 2025.
  • Biote's Asset Writedowns and Impairment's 5-year high stood at $773000.0 during Q1 2025, with a 5-year trough of -$270000.0 in Q3 2022.
  • For the 5-year period, Biote's Asset Writedowns and Impairment averaged around $245937.5, with its median value being $117000.0 (2024).
  • In the last 5 years, Biote's Asset Writedowns and Impairment tumbled by 55000.0% in 2022 and then soared by 138461.54% in 2024.
  • Over the past 5 years, Biote's Asset Writedowns and Impairment (Quarter) stood at $291000.0 in 2021, then plummeted by 81.1% to $55000.0 in 2022, then decreased by 29.09% to $39000.0 in 2023, then skyrocketed by 1384.62% to $579000.0 in 2024, then fell by 16.06% to $486000.0 in 2025.
  • Its Asset Writedowns and Impairment stands at $486000.0 for Q3 2025, versus $327000.0 for Q2 2025 and $773000.0 for Q1 2025.